Ligand Pharmaceuticals Announces $625 Million Convertible Notes Pricing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Ligand Pharmaceuticals announced the pricing of $625.0 million aggregate principal amount of 0.0% convertible senior notes due 2031 in a private placement to persons reasonably believed to be qualified institutional buyers. Upon conversion, Ligand will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Ligand's common stock or a combination of cash and shares of Ligand's common stock, at Ligand's election, in respect of the remainder, if any, of Ligand's conversion obligation in excess of the aggregate principal amount of the notes being converted. The conversion rate will initially be 2.9916 shares of Ligand's common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $334.27 per share of Ligand's common stock). The initial conversion price of the notes represents a premium of approximately 27.5% over the last reported sale price of Ligand's common stock on the Nasdaq Global Market on June 22, 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LGND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LGND
Wall Street analysts forecast LGND stock price to fall
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 319.430
Low
220.00
Averages
237.20
High
270.00
Current: 319.430
Low
220.00
Averages
237.20
High
270.00
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ligand Pharmaceuticals Prices $625M Convertible Notes Offering
- Offering Size: Ligand Pharmaceuticals has priced a $625 million offering of convertible senior notes due September 15, 2031, reflecting the company's confidence in future financing and expected to strengthen its capital structure.
- Conversion Terms: The initial conversion rate is set at 2.9916 shares of common stock per $1,000 principal amount, with a conversion price of approximately $334.27, representing a 27.5% premium over the last reported stock price, indicating market expectations for future growth.
- Use of Proceeds: The estimated net proceeds of approximately $605.3 million will be allocated for convertible note hedge transactions, repurchasing 228,859 shares, and general corporate purposes, showcasing the company's proactive capital management strategy.
- Market Reaction: The offering is expected to close on June 25, 2026, and if the underwriters exercise their option to purchase additional notes, net proceeds could reach $678.2 million, further enhancing the company's competitive position in the biopharmaceutical sector.
See More
Ligand Pharmaceuticals Prices $625 Million Convertible Note Offering
- Expanded Financing: Ligand Pharmaceuticals announced a $625 million upsized offering of 0.0% convertible notes, expected to enhance the company's financial flexibility and support its long-term capital strategy, reflecting confidence in future growth.
- Additional Purchase Option: Initial purchasers have a 13-day option to buy up to an additional $75 million in notes, which could increase the total offering size to $700 million if fully exercised, further enhancing capital-raising capabilities.
- Clear Use of Proceeds: The expected net proceeds of approximately $605.3 million will be allocated for convertible note hedge transactions, repurchasing 228,859 shares, and general corporate purposes, demonstrating strategic flexibility in capital management.
- Strategic Implications: This offering is viewed as an opportunistic capital raise designed to enhance financial flexibility, with the combination of share repurchases aimed at reducing potential dilution, aligning with shareholder interests and reflecting the company's commitment to shareholder value.
See More
Ligand Pharmaceuticals Raises $625 Million in Convertible Notes Offering
- Capital Raise: Ligand Pharmaceuticals announced the pricing of $625 million in 0.0% convertible senior notes, expected to close on June 25, 2026, enhancing financial flexibility and supporting future investments.
- Use of Proceeds: The offering is projected to yield approximately $605.3 million in net proceeds, with about $72.9 million allocated for convertible note hedge transactions and around $60 million for repurchasing 228,859 shares of common stock, aimed at offsetting potential dilution.
- Conversion Terms: Noteholders can convert their notes under specific conditions before June 15, 2031, with an initial conversion price of $334.27 per share, representing a 27.5% premium over the last reported price on June 22, 2026, which will impact future shareholder structure and market performance.
- Market Impact: The bond issuance and related hedge transactions may influence Ligand's common stock price, particularly during conversion and repurchase periods, potentially leading to market price fluctuations and affecting investor decisions.
See More
Mixed Market Close: Tech Stocks Decline Amid Leadership Changes
- Tech Stock Decline: Alphabet's stock fell over 5% following the announcement of Google DeepMind VP Jumper's departure, leading to a broader decline in major tech stocks, which may heighten investor uncertainty regarding the tech sector's future performance.
- Oil Price Volatility: Oil prices initially surged over 2% after Iran threatened to close the Strait of Hormuz, but later retreated due to reported progress in peace talks with the US, highlighting the direct impact of geopolitical tensions on market dynamics and prompting investors to reassess energy sector risks.
- Market Expectation Shift: The market is currently pricing in a 39% chance of a 25 basis point rate hike at the upcoming FOMC meeting, reflecting a cautious investor sentiment towards future monetary policy, which could influence market liquidity and investment strategies.
- Overseas Market Performance: European and Asian stock markets closed higher, with the Euro Stoxx 50 and Japan's Nikkei 225 rising by 0.29% and 1.55% respectively, indicating a divergence in global market trends that may provide some support for the US market.
See More
Mixed U.S. Stock Performance with Tech Stocks Leading Declines
- Tech Stock Decline: Alphabet's stock fell over 6%, leading the tech sector down after the announcement of Google DeepMind VP Jumper's departure to Anthropic PBC, raising concerns about the company's future and potentially impacting investor confidence.
- Market Volatility Factors: Stock index futures weakened overnight due to a more than 2% rise in oil prices following Iran's threat to close the Strait of Hormuz, although they recovered later due to reported progress in peace talks with the U.S., highlighting geopolitical influences on market dynamics.
- Bond Yield Changes: The 10-year U.S. Treasury yield rose to 4.503%, a one-week high, driven by Fed rate hike expectations and an upcoming $211 billion Treasury auction, which may exert pressure on the bond market.
- Overseas Market Performance: European and Asian stock markets saw gains, with the 10-year German bund yield falling to 2.946%, reflecting optimism about global economic recovery, which could provide support for the U.S. market.
See More
U.S. Stocks Edge Up, Nasdaq Hits 2.5-Week High
- Market Recovery: The Nasdaq 100 index rose by 0.50% to reach a 2.5-week high as the markets reopened after the holiday, driven by strong performances from chipmakers and AI infrastructure stocks, indicating a rebound in investor confidence towards tech equities.
- Oil Price Volatility: Although crude oil prices initially surged over 2% due to Iran's threat to close the Strait of Hormuz, they retreated after reports of 'major progress' in peace talks with the U.S., highlighting the short-term impact of geopolitical risks on market volatility and stock index futures.
- UK Political Shift: Following Prime Minister Keir Starmer's resignation, the market is keenly awaiting Andy Burnham's choice for Chancellor of the Exchequer, with concerns that an unqualified new chancellor could raise issues regarding deficits and borrowing, putting pressure on the British pound and reflecting the impact of political uncertainty on market sentiment.
- Rate Hike Expectations: The market is pricing in a 36% chance of a 25 basis point rate hike by the Federal Reserve at its meeting on July 28-29, while the European Central Bank has only a 10% chance of a rate hike at its next policy meeting, indicating differing expectations for future monetary policy that could influence investor asset allocation strategies.
See More
Ligand Pharmaceuticals Prices $625M Convertible Notes Offering
- Offering Size: Ligand Pharmaceuticals has priced a $625 million offering of convertible senior notes due September 15, 2031, reflecting the company's confidence in future financing and expected to strengthen its capital structure.
- Conversion Terms: The initial conversion rate is set at 2.9916 shares of common stock per $1,000 principal amount, with a conversion price of approximately $334.27, representing a 27.5% premium over the last reported stock price, indicating market expectations for future growth.
- Use of Proceeds: The estimated net proceeds of approximately $605.3 million will be allocated for convertible note hedge transactions, repurchasing 228,859 shares, and general corporate purposes, showcasing the company's proactive capital management strategy.
- Market Reaction: The offering is expected to close on June 25, 2026, and if the underwriters exercise their option to purchase additional notes, net proceeds could reach $678.2 million, further enhancing the company's competitive position in the biopharmaceutical sector.
See More
Ligand Pharmaceuticals Prices $625 Million Convertible Note Offering
- Expanded Financing: Ligand Pharmaceuticals announced a $625 million upsized offering of 0.0% convertible notes, expected to enhance the company's financial flexibility and support its long-term capital strategy, reflecting confidence in future growth.
- Additional Purchase Option: Initial purchasers have a 13-day option to buy up to an additional $75 million in notes, which could increase the total offering size to $700 million if fully exercised, further enhancing capital-raising capabilities.
- Clear Use of Proceeds: The expected net proceeds of approximately $605.3 million will be allocated for convertible note hedge transactions, repurchasing 228,859 shares, and general corporate purposes, demonstrating strategic flexibility in capital management.
- Strategic Implications: This offering is viewed as an opportunistic capital raise designed to enhance financial flexibility, with the combination of share repurchases aimed at reducing potential dilution, aligning with shareholder interests and reflecting the company's commitment to shareholder value.
See More
Ligand Pharmaceuticals Raises $625 Million in Convertible Notes Offering
- Capital Raise: Ligand Pharmaceuticals announced the pricing of $625 million in 0.0% convertible senior notes, expected to close on June 25, 2026, enhancing financial flexibility and supporting future investments.
- Use of Proceeds: The offering is projected to yield approximately $605.3 million in net proceeds, with about $72.9 million allocated for convertible note hedge transactions and around $60 million for repurchasing 228,859 shares of common stock, aimed at offsetting potential dilution.
- Conversion Terms: Noteholders can convert their notes under specific conditions before June 15, 2031, with an initial conversion price of $334.27 per share, representing a 27.5% premium over the last reported price on June 22, 2026, which will impact future shareholder structure and market performance.
- Market Impact: The bond issuance and related hedge transactions may influence Ligand's common stock price, particularly during conversion and repurchase periods, potentially leading to market price fluctuations and affecting investor decisions.
See More
Mixed Market Close: Tech Stocks Decline Amid Leadership Changes
- Tech Stock Decline: Alphabet's stock fell over 5% following the announcement of Google DeepMind VP Jumper's departure, leading to a broader decline in major tech stocks, which may heighten investor uncertainty regarding the tech sector's future performance.
- Oil Price Volatility: Oil prices initially surged over 2% after Iran threatened to close the Strait of Hormuz, but later retreated due to reported progress in peace talks with the US, highlighting the direct impact of geopolitical tensions on market dynamics and prompting investors to reassess energy sector risks.
- Market Expectation Shift: The market is currently pricing in a 39% chance of a 25 basis point rate hike at the upcoming FOMC meeting, reflecting a cautious investor sentiment towards future monetary policy, which could influence market liquidity and investment strategies.
- Overseas Market Performance: European and Asian stock markets closed higher, with the Euro Stoxx 50 and Japan's Nikkei 225 rising by 0.29% and 1.55% respectively, indicating a divergence in global market trends that may provide some support for the US market.
See More
Mixed U.S. Stock Performance with Tech Stocks Leading Declines
- Tech Stock Decline: Alphabet's stock fell over 6%, leading the tech sector down after the announcement of Google DeepMind VP Jumper's departure to Anthropic PBC, raising concerns about the company's future and potentially impacting investor confidence.
- Market Volatility Factors: Stock index futures weakened overnight due to a more than 2% rise in oil prices following Iran's threat to close the Strait of Hormuz, although they recovered later due to reported progress in peace talks with the U.S., highlighting geopolitical influences on market dynamics.
- Bond Yield Changes: The 10-year U.S. Treasury yield rose to 4.503%, a one-week high, driven by Fed rate hike expectations and an upcoming $211 billion Treasury auction, which may exert pressure on the bond market.
- Overseas Market Performance: European and Asian stock markets saw gains, with the 10-year German bund yield falling to 2.946%, reflecting optimism about global economic recovery, which could provide support for the U.S. market.
See More
U.S. Stocks Edge Up, Nasdaq Hits 2.5-Week High
- Market Recovery: The Nasdaq 100 index rose by 0.50% to reach a 2.5-week high as the markets reopened after the holiday, driven by strong performances from chipmakers and AI infrastructure stocks, indicating a rebound in investor confidence towards tech equities.
- Oil Price Volatility: Although crude oil prices initially surged over 2% due to Iran's threat to close the Strait of Hormuz, they retreated after reports of 'major progress' in peace talks with the U.S., highlighting the short-term impact of geopolitical risks on market volatility and stock index futures.
- UK Political Shift: Following Prime Minister Keir Starmer's resignation, the market is keenly awaiting Andy Burnham's choice for Chancellor of the Exchequer, with concerns that an unqualified new chancellor could raise issues regarding deficits and borrowing, putting pressure on the British pound and reflecting the impact of political uncertainty on market sentiment.
- Rate Hike Expectations: The market is pricing in a 36% chance of a 25 basis point rate hike by the Federal Reserve at its meeting on July 28-29, while the European Central Bank has only a 10% chance of a rate hike at its next policy meeting, indicating differing expectations for future monetary policy that could influence investor asset allocation strategies.
See More
